biote Corp. (NASDAQ:BTMD - Get Free Report) major shareholder Guines Llc bought 8,801 shares of biote stock in a transaction dated Monday, April 21st. The stock was purchased at an average price of $3.27 per share, with a total value of $28,779.27. Following the completion of the purchase, the insider now owns 4,173,101 shares in the company, valued at $13,646,040.27. This trade represents a 0.21 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.
Guines Llc also recently made the following trade(s):
- On Thursday, April 17th, Guines Llc acquired 6,874 shares of biote stock. The stock was purchased at an average cost of $3.29 per share, with a total value of $22,615.46.
- On Wednesday, April 9th, Guines Llc bought 13,532 shares of biote stock. The shares were purchased at an average cost of $3.21 per share, for a total transaction of $43,437.72.
- On Monday, April 7th, Guines Llc purchased 43,378 shares of biote stock. The shares were acquired at an average price of $3.15 per share, with a total value of $136,640.70.
- On Thursday, April 3rd, Guines Llc acquired 7,321 shares of biote stock. The stock was acquired at an average cost of $3.24 per share, for a total transaction of $23,720.04.
- On Monday, March 31st, Guines Llc bought 106,000 shares of biote stock. The shares were acquired at an average cost of $3.32 per share, with a total value of $351,920.00.
- On Monday, March 17th, Guines Llc purchased 100 shares of biote stock. The stock was acquired at an average cost of $3.74 per share, for a total transaction of $374.00.
- On Thursday, March 13th, Guines Llc acquired 750,000 shares of biote stock. The shares were bought at an average cost of $3.22 per share, with a total value of $2,415,000.00.
biote Price Performance
NASDAQ BTMD opened at $3.43 on Thursday. The company has a fifty day moving average price of $3.85 and a 200-day moving average price of $5.08. The firm has a market cap of $187.66 million, a price-to-earnings ratio of 13.19 and a beta of 1.17. biote Corp. has a 1 year low of $3.04 and a 1 year high of $8.44.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP increased its stake in biote by 0.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 681,524 shares of the company's stock valued at $4,211,000 after buying an additional 3,065 shares during the last quarter. State Street Corp increased its position in shares of biote by 13.7% during the third quarter. State Street Corp now owns 475,491 shares of the company's stock valued at $2,653,000 after acquiring an additional 57,290 shares during the last quarter. Kanen Wealth Management LLC bought a new stake in biote during the fourth quarter worth $1,791,000. Northern Trust Corp boosted its position in biote by 9.9% in the fourth quarter. Northern Trust Corp now owns 288,336 shares of the company's stock worth $1,782,000 after purchasing an additional 25,873 shares during the last quarter. Finally, Hillsdale Investment Management Inc. bought a new position in biote in the 4th quarter valued at $1,561,000. 21.68% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Separately, Craig Hallum cut their target price on biote from $12.00 to $8.00 and set a "buy" rating on the stock in a research report on Thursday, March 13th.
Check Out Our Latest Stock Analysis on biote
biote Company Profile
(
Get Free Report)
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
